Figure 2.
PFS of 17p− CLL patients from the CLL8 trial (both treatment arms combined) defined by unmutated (n = 40; green) and mutated (n = 11; blue) IGHV status (median of 11.0 versus 16.2 months, p = 0.359).
PFS of 17p− CLL patients from the CLL8 trial (both treatment arms combined) defined by unmutated (n = 40; green) and mutated (n = 11; blue) IGHV status (median of 11.0 versus 16.2 months, p = 0.359).
